Ruxolitinib cream is effective for atopic dermatitis and prurigo nodularis, with low adverse event rates in long-term use. The cream reduces the need for other topical treatments and biologics in ...
Recent network meta-analyses identified the relative outcomes of various vitiligo monotherapies on vitiligo at 6 months.
Twice-daily application of ruxolitinib cream demonstrated an ability to reduce itching and blistering in prurigo nodularis, a ...
However, for the Company, 2024 was both a “year of restructuring” amidst challenges and a “year of breakthroughs” with emerging potentials. Although the overall performance is experiencing short-term ...
New York, USA, Feb. 28, 2025 (GLOBE NEWSWIRE) -- OPZELURA Continues to Revolutionize the Dermatology Market with Strong Market Uptake | DelveInsight OPZELURA (ruxolitinib cream) has shown strong ...
TRuE-PN1 Study: 44.6% of PN patients using ruxolitinib cream saw ≥4-point WI-NRS4 improvement at Week 12 vs. 20.6% with vehicle control. TRuE-PN2 Study: The primary endpoint missed statistical ...
OPZELURA (ruxolitinib cream) has shown strong market growth, driven by increasing adoption in dermatological conditions like vitiligo and atopic dermatitis. Its unique positioning as the first FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results